strophantin for covid

cedric

http://www.herzinfarkt-alternativen.de/wp-content/uploads/2021/01/OUABAIN-–-A-Drug-for-Treatment-of-COVID-19.pdf

OUABAIN – A Drug for Treatment of COVID-19
Knut Sroka*
Vizelinstrasse 58, 22529 Hamburg, Germany
*Corresponding author: Knut Sroka, Hamburg, Germany; E-Mail: dr.sroka@gmx.de
Received: June 28, 2020; Accepted: July 06, 2020; Published: July 15, 2020

Abstract
There is an enormous demand for effective medication against COVID-19. The cardiac steroid ouabain has properties qualifying it as a drug in the battle
against the actual corona pandemic. Strong antiviral properties against different viruses including SARS- CoV-2 have been circumstantiated. Ouabain
increases the resistance to hypoxia and exerts protecting effects in cytokine dysregulation. The application of ouabain could to be useful at any stage of
COVID-19.
Keywords: Antiviral, ARS-CoV-2, COVID-19, Cytokine dysregulation, Ouabain
Introduction
SARS-CoV-2 has locked down the world. Human victims and the
economic damage are tremendous. The need for effective medication
in COVID-19 is immense. Ouabain is a drug extracted from the
seeds of an African vine. The favorable effects of this drug in different
forms of heart disease have been well known for longtime. Nowadays
ouabain is used in cancer and antiviral research. In this article the
antiviral properties of ouabain and its potential effects in treating
COVID-19 patients are presented.
Specific Qualities of Ouabain
Strong Antiviral Properties
Ouabain, a cadiotonic steroid, is part of the cardioactive glycosides.
Ouabain has strong antiviral properties. Three examples: (a) The
replication of influenza A virus will be inhibited almost completely by
ouabain. 24 h post-infection with influenza A the viral titers were found
to be decreased by 99.1% with ouabain treatment [1]. (b) Ouabain was
shown to reduce the replication rate of Ebola virus by 50% within 48
h [2]. (c) Ouabain was identified as having robust efficiency against
Japanese Encephalitis Virus (JEV) infection. JEV infection was blocked
by ouabain at the replication stage within 24 h. Furthermore, it was
proven that ouabain significantly reduced the morbidity and mortality
caused by JEV in a BALB/c mouse model [3]. The ability of ouabain
to inhibit virus replication has been proven for different other viruses
with a lipid envelope: Herpes simplex virus, vaccinia poxvirus, murine
leukemia virus, SARS corona viruses, and others. "